Transgenomic : Investor Relations

Transgenomic, Inc. Invites You to Join Its Second Quarter 2001 Conference Call On the Web

SAN JOSE, Calif. and OMAHA, Neb., July 16 /PRNewswire/ -- In connection with Transgenomic, Inc.'s reporting of second quarter financial results, you are invited to listen to its conference call that will be broadcast live over the Internet on Wednesday, August 1 at 5:00 p.m., Eastern Time, with Collin D'Silva, chief executive officer. Transgenomic, Inc. (Nasdaq: TBIO) will release its financial results on Wednesday, August 1 at 4:00 p.m. ET.

What:	Transgenomic, Inc.'s Second Quarter 2001 Financial Results Conference Call
When:	Wednesday, August 1, 2001, 5:00 p.m. ET
Where:	http://www.videonewswire.com/event.asp?id=198
How:	Live over the Internet -- Simply log on to the web at the address above
Contact:	Mitchell L. Murphy, Investor Relations, Transgenomic, Inc., +1-402-452-5437

Future release of quarterly financial results and conference calls will be scheduled with similar timing, on the fifth Wednesday after the end of each quarter. The date for release of third quarter 2001 financial results will be October 31.

If you are unable to participate during the live webcast, the call will be archived at http://www.videonewswire.com/event.asp?id=198 . A link to this site will also be located on the company's website. In addition, an archived recording of the call can be accessed by way of telephone from 8:00 p.m. ET on August 1 through Wednesday, August 15, 2001, midnight ET. Simply dial +1-402-530-9316 from any telephone.

(Minimum requirements to listen to web broadcast are: RealPlayer software, downloadable free from http://www.real.com/products/player/index.html; and at least a 28.8 kbps connection to the Internet. If you experience problems listening to the broadcast, send an e-mail to webmaster@vdat.com.)

Transgenomic provides versatile and innovative research tools and related consumable products to the life sciences industry. Its WAVE® Nucleic Acid Fragment Analysis System can be used for variation detection, size-based double-strand DNA separation and analysis, single-strand DNA separation and analysis and DNA purification. When used for variation detection, these tools enable researchers to discover and understand variation in the human genetic code, or genome, in order to accelerate and improve drug development and diagnostics. Transgenomic believes the WAVE System will become a leading tool to analyze genetic variations as it allows researchers to analyze both known and unknown genetic variations faster, with more accuracy and at a lower cost than other commercially available techniques. To date, there are over 600 WAVE Systems placed in over 25 countries around the world.

Its specialty chemicals products consist of a wide variety of nucleic acid-based products and services for the life sciences sector, including nucleic acid building blocks ("phosphoramidites"), fluorescent markers and dyes and associated reagents. In addition, the company is a principle provider of oligomimetics and specialty chemicals. Oligomimetics are chemically-modified DNA and RNA molecules exhibiting proven enhancements in stability, bioavailability, specificity and efficacy making them excellent candidates for use in clinical applications such as genetic diagnostics and therapeutics. Oligomimetics also exhibit higher affinity and specificity than regular DNA making them excellent candidates for DNA diagnostics and chip technology.

For more information about the innovative genomics research tools developed and marketed by Transgenomic, please visit the company's website at http://www.transgenomic.com.

This press release may contain forward-looking statements that reflect management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results. Such statements are subject to certain factors, risks and uncertainties described from time to time in Transgenomic, Inc.'s reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release.